{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:digoxin",
  "owner": "cardio",
  "kind": "drug",
  "slug": "digoxin",
  "name": "Digoxin",
  "aliases": [
    "Lanoxin"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Digoxin, sold as Lanoxin, is a cardiac glycoside, a medicine taken by mouth in the form read here. The US label read, for Lanoxin tablets, lists three uses: mild to moderate heart failure in adults; increasing the strength of the heart muscle contraction in pediatric patients with heart failure; and controlling the ventricular response rate (how fast the lower chambers beat) in adults with chronic atrial fibrillation. For adults with heart failure the label says it improves symptoms, as shown by better exercise capacity and fewer heart-failure hospitalizations and emergency care visits, while having no effect on mortality. Its pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies.",
  "summary_technical": "RxNorm ingredient 3407; UNII 73K4184T59. RxClass lists the FDA established pharmacologic class Cardiac Glycoside; the record is filed under the class page Cardiac glycosides (digoxin) on that evidence. The label read is the Advanz Pharma (US) Corp. label for Lanoxin tablets, application NDA020405, effective 2024-12-05 in openFDA. The Lanoxin injection label (NDA009330) and generic labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "3407",
      "normalized_value": "3407",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "73K4184T59",
      "normalized_value": "73K4184T59",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D004077",
      "normalized_value": "D004077",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "heart-failure",
        "arrhythmias"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says all of digoxin's actions come from its effect on the sodium-potassium ATPase enzyme, which raises the calcium available inside heart muscle cells."
  },
  "content_digest": "2c77036e6fc89c1fee24f6afd40546c689ef7aad1873464f7ee79de11fe47834",
  "review": {
    "content_digest": "2c77036e6fc89c1fee24f6afd40546c689ef7aad1873464f7ee79de11fe47834",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-digoxin-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:digoxin",
      "category": "descriptive",
      "statement": "The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.",
      "context": {
        "id": "cardio:ctx-fda-lanoxin-label-us",
        "label": "Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets",
        "recipient": "adult",
        "population": "Adults with mild to moderate heart failure, and adult patients with chronic atrial fibrillation, as the indications section of the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with mild to moderate heart failure",
            "Adult patients with chronic atrial fibrillation"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.1 Heart Failure in Adults",
          "applicability_note": "Label passage quoted in the research quote table (LB-05, LB-10, LB-08).",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.3 Atrial Fibrillation in Adults",
          "applicability_note": "Label passage quoted in the research quote table (LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241205.",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "be3c1549d3c14db24d3d34293e407d100079b063ac994b1845d9bd3a9abfb809",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-digoxin-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-digoxin-label-paediatric",
      "owner": "cardio",
      "subject_entity_id": "cardio:digoxin",
      "category": "descriptive",
      "statement": "The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.",
      "context": {
        "id": "cardio:ctx-fda-lanoxin-label-paediatric",
        "label": "Children with heart failure, as described in the US label of Lanoxin tablets",
        "recipient": "child",
        "population": "Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Pediatric patients, as the label states; no ages given in the passage read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Pediatric patients with heart failure"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients",
          "applicability_note": "Label passage quoted in the research quote table (LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].pediatric_use[0], 8.4 Pediatric Use",
          "applicability_note": "The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241205.",
          "snapshot": {
            "id": "cardio:openfda-label-lanoxin-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:12Z",
            "content_hash": "9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd",
            "source_effective_date": "2024-12-05",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-lanoxin",
            "source_type": "regulator",
            "title": "openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d91e3646-4c63-4512-ab22-db39c085c4dc%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-digoxin.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "95c59222e2917e3acc9793729a94ebefadfcefeb059ee209a3bc670ef1e88dcc",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-digoxin-label-paediatric.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists mild to moderate heart failure in adults as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:heart-failure",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-digoxin-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists control of the ventricular response rate in adults with chronic atrial fibrillation as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:atrial-fibrillation",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-digoxin-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "The FDA established pharmacologic class of digoxin in RxClass is Cardiac Glycoside",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:cardiac-glycosides-digoxin",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-3407-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/digoxin/",
  "context_path": "api/v1/context/cardio--digoxin.md"
}
